The pharma market in Poland will develop at the average annual growth rate of 4.8% between 2016 and 2021, according to a new report from Poland-based market research firm PMR.
The market will be driven by drugs acting on the blood and blood forming organs as well as endocrine medications. The next few years will be also marked by significant legal changes.
Stable market growth in 2016-2021
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze